MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
Recognition highlights the hospital network’s decade-long investment in analytics and AI-driven healthcare, supporting improved outcomes, efficiency, and affordability.
Developed by the Sudha Gopalakrishnan Brain Centre, the publicly accessible ANCHOR atlas maps over 200 brainstem structures at cellular resolution, offering new possibilities for neuroscience research and clinical applications
Collaboration aims to accelerate medicinal chemistry decision-making, reduce synthesis burden and strengthen data-secure AI adoption in drug discovery
Pharmaceutical R&D veteran brings over 20 years of expertise in formulation development, ANDA filings, and regulated-market product innovation to strengthen MSN Laboratories’ global growth ambitions
Partnership discussions focus on clinical validation, real-world evidence generation and adoption of indigenous diagnostic technologies across healthcare settings
The award places the company in the top 5% globally
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
Strategic collaboration aims to strengthen clinical capabilities, enhance patient experience and improve fertility treatment outcomes through scientific expertise, technology and data-driven care
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
Subscribe To Our Newsletter & Stay Updated
